Our partner lab in Miami, Florida (USA) has developed highly efficacious products in the regenerative medicine market through extensive research and development spanning over two decades. They have created a novel product that has taken Exosome Therapeutics to a new level. The product is guaranteed to contain several trillion exosomes per each 1.5ml vial, making it the most potent exosome product available on the market.
In a recent third-party analysis conducted by a leading FDA sanctioned testing laboratory, the Amnio Matrix product manufactured by our partner lab was found to contain 6-7 trillion exosomes per 1.5ml vial across three different batches. To confirm the identity of the extracellular vesicles (ECVs) as exosomes, the size and surface protein expression of the particles were measured. The average mean and mode size of the particles in the analysis was found to be 113.1nm, which is within the expected size range of exosomes. Furthermore, a complete surface protein analysis demonstrated a balanced expression of CD9, CD63, and CD81 on the exosomes.
It is important to note that other companies providing amnio-derived exosome products may screen and filter particles up to 200 nm in size, which may include non-exosomal particles. Even with a stringent screening process, the Amnio Matrix product developed by our partner lab has been found to contain 5-10 times more exosomes per cc than any other exosome product currently available on the market. These findings suggest that the Amnio Matrix product manufactured by our partner lab is a highly potent and reliable source of exosomes for use in regenerative medicine.
In addition, many other companies clone their growth factors (or other exosome cargos) leading to a reduced bioavailability resulting in diminishing returns. Amino Matrix undergoes rigorous donor screening and contains 1,600 growth factors mimicking being inside the placenta. In simple terms, it’s putting your cells in an environment they haven’t been exposed to since you were inside the womb.
Amnio Matrix product has been shown to have a high concentration of exosomes, with 6-7 trillion exosomes per 1.5 ml vial, as measured by a third-party laboratory. The size of the exosomes was also measured, with an average mean/mode of 113.1 nm, which is within the expected size range for exosomes. Additionally, a protein analysis of the surface markers CD9, CD63, and CD81 was conducted, which showed a robust balance of these proteins, further confirming the exosome identity of the isolated particles.
Overall, based on the information provided, the Amnio Matrix product appears to be a highly concentrated and characterized exosome product derived from amniotic fluid. However, further information would be needed to fully evaluate its efficacy and safety for use in regenerative medicine.
Timeline For Matrix Exosomes
The timeline of healing effects commonly reported with amino exosomes
The timeline of healing effects associated with amnio exosomes can vary depending on the individual and the condition being treated. However, many patients have reported experiencing some degree of improvement within a few weeks to a few months after treatment.
For example, patients with joint pain or injuries may notice reduced pain and improved mobility within a few weeks, while patients with skin conditions or wounds may notice improved healing and skin regeneration within a few months. It’s important to note that individual results may vary, and it’s always best to consult with a healthcare professional to determine the best treatment plan for your specific condition.
We highly encourage baseline data (blood work, health metrics: Oura ring, Fitbit, Apple Watch) in order to visualize the often unfelt workings of our inner health.
Clinically we see mood and slight vision (brightening) in the first 48 hours immediately. Then around day 5-7 reports of improved VO2max, HRV and deep sleep. From there the regenerative process continues and further reports of progress are then commented on typically 3-5 months later.
According to current patient reports (by time frame) to name a few:
- Mood improvements (prefrontal cortex associated)
- Reduced tremors
- Heart rate variability increases
- Sleep score improvements
- Reduced joint pain and improved muscular recovery
- Increase breath holding capacity & VO2 max improvement
- Food sensitivities improvements
- Significant inflammation reduction
- Faster tissue healing
- Cardiovascular blood biomarker improvement
- Bone regrowth in non-union fractures
- Improved vision and hearing
- Cognitive improvement and motivation increases
- Improved emotional regulation (especially in TBI’s)
Safety & Research Of Amnio Matrix
The safety of Amnio Matrix exosomes has not been evaluated by the U.S. Food and Drug Administration (FDA) or any other regulatory agency. The use of exosomes as a therapeutic agent is still an emerging field, and more research is needed to fully understand their safety and efficacy. However, the manufacturer of Amnio Matrix claims that their exosomes are rigorously tested for safety and quality control before being made available for use. It is important to note that any use of exosomes as a therapeutic agent should be done under the guidance of a qualified healthcare professional.
Every lot is made in 250 vial batches and is labeled and filed according to the FDA guidelines.
There is growing interest in the potential therapeutic applications of exosomes, and there are numerous studies investigating the use of exosomes in various diseases and conditions.
Some recent studies have investigated the use of exosomes derived from amniotic fluid or amniotic membrane for wound healing, tissue regeneration, and treatment of inflammatory disorders.
For example, a study published in the journal Stem Cells and Development in 2021 found that exosomes derived from human amniotic fluid had anti-inflammatory effects in a mouse model of inflammatory bowel disease. Another study published in the journal Frontiers in Bioengineering and Biotechnology in 2020 investigated the use of amniotic membrane-derived exosomes for treating chronic wounds in diabetic mice, and found that the exosomes promote wound healing and tissue regeneration.
Neurodegenerative diseases like Alzheimer’s disease cause neuronal cell death, and neuroinflammation plays a crucial role in it. Microglia cells in the brain control the levels of a protein called amyloid beta (Aβ), which is linked to Alzheimer’s disease.
Exosomes from amniotic fluid (hAFECVs) can help treat this by releasing small bubbles called exosomes that have anti-inflammatory properties. In this study, researchers looked at how these exosomes affect microglia cells that cause inflammation and how they interact with neurons. They found that they reduced inflammation in microglia cells and prevented oxidative stress and cell death in neurons exposed to both microglia and Aβ. This suggests that they could be a potential therapy for neuroinflammatory conditions, including Alzheimer’s disease.
Multiple anecdotal reports from clinics have reported TBI resolution and what appears to be prefrontal cortex repair and dopamine up-regulation alongside other NT’s. However, this is only clinic to clinic data at the moment.
Case study research is limited due to the current regulatory climate.
Amnio Matrix Addition Information
Our partner lab has developed a groundbreaking proprietary process to sterilize their Matrix product. Unlike other stem cell and exosome products on the market, there is no need to immediately move from thawing to injection with Matrix.
This is due to their breakthrough flash UV sterilization process prior to freezing, which ensures that the solution remains stable and sterile after thawing as long as it is kept cryogenically stored. Due to the size of the exosomes (1000 times smaller than a stem cell) the ability to IV allows for full body saturation including crossing the blood brain barrier.
Over 80% of stem cells are trapped in the lungs and furthermore destroyed by inflammation when IV’d. Whereas exosomes are not.
Matrix can also be combined with PRP if preferred. This provides a significant cost benefit for clinics and their patients while maintaining the highest amount of exosomes compared to all other products in the market. The rare trifecta of lower cost, greater convenience, and greater efficacy make Amnio Matrix an exceptional choice for regenerative medicine.
Amnio Matrix can be used for a variety of indications in regenerative medicine, including wound healing, pain management, and tissue repair. The product is also marketed for use in orthopedics, sports medicine, and aesthetic applications.
However, it’s important to note that the efficacy and safety of Amnio Matrix for these indications have not been evaluated by the FDA, and the product is not currently approved for any specific medical use.
It’s also worth noting that the use of exosomes and other extracellular vesicles in regenerative medicine is still an emerging field, and more research is needed to fully understand their potential therapeutic applications.